{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:50:32Z","timestamp":1762505432334},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"831","license":[{"start":{"date-parts":[[1995,1,1]],"date-time":"1995-01-01T00:00:00Z","timestamp":788918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1995,1,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Hypercalcaemia associated with malignancy is generally thought to carry a poor prognosis. Of 47 consecutive patients with hypercalcaemia and malignancy, serum parathyroid hormone (PTH) was elevated in seven, consistent with co-existing hyperparathyroidism. Median survival from onset of hypercalcaemia in these seven patients was 817 days; compared to 33 days in the remaining 40 patients with hypercalcaemia of malignancy, in whom PTH was suppressed (p = 0.007). Among patients with hypercalcaemia of malignancy, plasma PTH-related protein (PTHrP) concentration showed no correlation with survival (r2 = 2.1%), but one patient with increased levels of both PTH and PTHrP survived only nine days after the onset of hypercalcaemia. A raised PTH had a positive predictive value of 86% for survival &amp;gt; 100 days, and of 71% for survival &amp;gt; 1 year. A raised plasma PTHrP predicted death within 100 days with a positive predictive value of 69%. We conclude that measurement of serum PTH is indicated in patients with hypercalcaemia and malignancy to identify the 15% with hyperparathyroidism, since this is associated with prolonged survival. In patients with hyperparathyroidism, assay of plasma PTHrP may indicate concurrent hypercalcaemia of malignancy, with an associated poor prognosis.<\/jats:p>","DOI":"10.1136\/pgmj.71.831.28","type":"journal-article","created":{"date-parts":[[2008,12,29]],"date-time":"2008-12-29T21:25:21Z","timestamp":1230585921000},"page":"28-31","source":"Crossref","is-referenced-by-count":35,"title":["Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism"],"prefix":"10.1093","volume":"71","author":[{"given":"A C J","family":"Hutchesson","sequence":"first","affiliation":[{"name":"Selly Oak Hospital , Raddlebarn Road, Birmingham B29 6JD , UK"},{"name":"Department of Clinical Biochemistry"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N J","family":"Bundred","sequence":"additional","affiliation":[{"name":"Department of Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W A","family":"Ratcliffe","sequence":"additional","affiliation":[{"name":"Wolfson Research Laboratories, Queen Elizabeth Hospital , Birmingham B15 2TH , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1995,1,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-112-7-499","article-title":"Cancer-associated hypercalcaemia: morbidity and mortality","volume":"112","author":"Ralston, S.H.; Gallacher, S.J.; Patel, U.; Campbell, J.; Boyle, I.T.","year":"1990","unstructured":"Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcaemia: morbidity and mortality. Ann Intern Med 1990; 112: 499-504.","journal-title":"Ann Intern Med"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/clinchem\/38.11.2171","article-title":"Parathyroid hormone-related protein; structure, function and measurement","volume":"38","author":"Burtis, W.J.","year":"1992","unstructured":"Burtis WJ. Parathyroid hormone-related protein; structure, function and measurement. Clin Chem 1992; 38: 2171-83.","journal-title":"Clin Chem"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/clinchem\/37.5.678","article-title":"Development and validation of a two-site immunoradiometric assay for parathyrin-related protein in unextracted plasma","volume":"37","author":"Ratcliffe, W.A.; Norbury, S.; Heath, D.A.; Ratcliffe, J.G.","year":"1991","unstructured":"Ratcliffe WA, Norbury S, Heath DA, Ratcliffe JG. Development and validation of a two-site immunoradiometric assay for parathyrin-related protein in unextracted plasma. Clin Chem 1991; 37: 678-85.","journal-title":"Clin Chem"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJM199004193221603","article-title":"Immunochemical characterisation of circulating parathyroid hormone-related protein in patients with humoral hypercalcaemia of cancer","volume":"322","author":"Burtis, W.J.; Brady, T.G.; Orloff, J.J.","year":"1990","unstructured":"Burtis WJ, Brady TG, Orloff JJ, et al. Immunochemical characterisation of circulating parathyroid hormone-related protein in patients with humoral hypercalcaemia of cancer. N Engl J Med 1990; 322: 1106-12.","journal-title":"N Engl J Med"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/clinchem\/39.3.414","article-title":"Clinical and laboratory studies of a new immunoradiometric assay of parathyroid hormone-related protein","volume":"39","author":"Fraser, W.D.; Robinson, J.; Lawton, R.","year":"1993","unstructured":"Fraser WD, Robinson J, Lawton R, et al. Clinical and laboratory studies of a new immunoradiometric assay of parathyroid hormone-related protein. Clin Chem 1993; 39: 414-9.","journal-title":"Clin Chem"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0140-6736(92)90220-W","article-title":"Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia","volume":"339","author":"Ratcliffe, W.A.; Hutchesson, A.C.J.; Bundred, N.J.; Ratcliffe, J.G.","year":"1992","unstructured":"Ratcliffe WA, Hutchesson ACJ, Bundred NJ, Ratcliffe JG. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet 1992; 339: 164-7.","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jso.2930370104","article-title":"Malignancy and concomitant hyperparathyroidism","volume":"37","author":"Strodel, W.E.; Thomson, N.W.; Eckhauser, F.E.; Knol, J.A.","year":"1988","unstructured":"Strodel WE, Thomson NW, Eckhauser FE, Knol JA. Malignancy and concomitant hyperparathyroidism. J Surg Oncol 1988; 37: 10-2.","journal-title":"J Surg Oncol"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2265.1993.tb00526.x","article-title":"Coincidental occurrence of primary hyperparathyroidism and cancer-associated hypercalcaemia in a middle-aged man","volume":"38","author":"Gallacher, S.J.; Fraser, W.D.; Farquharson, M.A.","year":"1993","unstructured":"Gallacher SJ, Fraser WD, Farquharson MA, et al. Coincidental occurrence of primary hyperparathyroidism and cancer-associated hypercalcaemia in a middle-aged man. Clin Endocrinol 1993; 38: 433-7.","journal-title":"Clin Endocrinol"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/bmj.304.6837.1284","article-title":"Hypercalcaemia: changing causes over the last 10 years","volume":"304","author":"Greaves, I.; Grant, A.J.; Heath, D.A.; Michael, J.; Adu, D.","year":"1992","unstructured":"Greaves I, Grant AJ, Heath DA, Michael J, Adu D. Hypercalcaemia: changing causes over the last 10 years. BMJ 1992; 304: 1284.","journal-title":"BMJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0889-8529(18)30357-8","article-title":"Primary hyperparathyroidism. Clinical presentation and factors influencing clinical management","volume":"18","author":"Heath, D.A.","year":"1989","unstructured":"Heath DA. Primary hyperparathyroidism. Clinical presentation and factors influencing clinical management. Endocrinol Metab Clin N Am 1989; 18: 631-46.","journal-title":"Endocrinol Metab Clin N Am"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/pgmj.69.814.640","article-title":"Parathyroid hormone-related protein as a tumour marker in humoral hypercalcaemia associated with malignancy","volume":"69","author":"Hutchesson, A.C.J.; Dunne, F.; Bundred, N.J.; Gee, H.; Ratcliffe, W.A.","year":"1993","unstructured":"Hutchesson ACJ, Dunne F, Bundred NJ, Gee H, Ratcliffe WA. Parathyroid hormone-related protein as a tumour marker in humoral hypercalcaemia associated with malignancy. Postgrad Med J 1993; 69: 640-2.","journal-title":"Postgrad Med J"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0169-6009(91)90040-7","article-title":"Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy","volume":"12","author":"Fraser, W.D.; Logue, F.C.; Gallacher, S.J.","year":"1991","unstructured":"Fraser WD, Logue FC, Gallacher SJ, et al. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy. Bone Mineral 1991; 12: 113-21.","journal-title":"Bone Mineral"},{"key":"ref_13","article-title":"Statistical methods in laboratory medicine","author":"Strike, P.W.","year":"1991","unstructured":"Strike PW. Statistical methods in laboratory medicine. Oxford: Butterworth-Heinemann, 1991."},{"key":"ref_14","first-page":"139","article-title":"Treatment of hypercalcaemia of malignancy. Bailliere's Clin Endocrinol Metab","volume":"4","author":"Heath, D.A.","year":"1990","unstructured":"Heath DA. Treatment of hypercalcaemia of malignancy. Bailliere's Clin Endocrinol Metab 1990; 4: 139-45."}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/71\/831\/28\/50218711\/postgradmedj-71-28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/71\/831\/28\/50218711\/postgradmedj-71-28.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T22:03:26Z","timestamp":1683756206000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/71\/831\/28\/7044133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,1,1]]},"references-count":14,"journal-issue":{"issue":"831","published-online":{"date-parts":[[1995,1,1]]},"published-print":{"date-parts":[[1995,1,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.71.831.28","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1995,1]]},"published":{"date-parts":[[1995,1,1]]}}}